Drug intelligence / Profile preview

dibotermin alfa + absorbable collagen sponge

Development stage
Unknown
Lead developer
Medtronic
Modality
Recombinant Proteins and Enzymes, Implantable Devices → Device-based Delivery → Drug Delivery Systems
Administration
Implant
01

Overview

Dibotermin alfa + absorbable collagen sponge is a combination product containing **dibotermin alfa**, a recombinant human bone morphogenetic protein-2 (**rhBMP-2**) together with an **absorbable collagen sponge** (ACS), most commonly bovine type I collagen[1][3][5]. Dibotermin alfa acts as a potent **osteoinductive protein**: it binds to receptors on the surface of mesenchymal cells, inducing their differentiation into cartilage- and bone-forming cells and promoting new trabecular bone formation at the site of implantation[1][5][3]. The absorbable collagen sponge serves as a carrier matrix, localizing the protein at the bone defect site and is fully resorbed as new bone forms[3][7]. The product is primarily indicated as an implant in adults for (1) single-level lumbar interbody spine fusion as a substitute for autogenous bone graft in degenerative disc disease, and (2) as an adjunct to standard care for the treatment of **acute tibia fractures** using open fracture reduction and intramedullary unreamed nail fixation, aimed at patients at high risk of non-union[1][2][3][5]. Faster fracture healing, reduced infections, and reduced need for secondary intervention have been observed[5]. The main marketed product is **InductOs**[2][3][5].

Brand names
InductOs
Other names
recombinant human bone morphogenetic protein-2 + absorbable collagen spongerhBMP-2 + absorbable collagen sponge
02

Targets

BMPR1ABMPR2 (Bone morphogenetic protein receptor type II)BMPR1B

Beyond the preview

Go deeper on dibotermin alfa + absorbable collagen sponge.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dibotermin alfa + absorbable collagen sponge.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call